Bart Biesmans

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

Arnaud Roth, Sabine Tejpar, Mauro Delorenzi et al. · Journal of Clinical Oncology · 2009 · 1.2K citations · Full text

Medicine, Oncology, Surgery +17

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Wendy De Roock, Hubert Piessevaux, Joris De Schutter et al. · Annals of Oncology · 2007 · 827 citations · Full text

Medicine, Oncology, Radiology +12

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

Bart Jacobs, Wendy De Roock, Hubert Piessevaux et al. · Journal of Clinical Oncology · 2009 · 368 citations · Full text

Medicine, Oncology, Pharmacology +17

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Hans Prenen, Jef De Schutter, Bart Jacobs et al. · Clinical Cancer Research · 2009 · 293 citations · Full text

Medicine, Oncology, Pharmacology +17